Edoxaban versus warfarin in patients with atrial fibrillation.
暂无分享,去创建一个
E. Antman | M. Ezekowitz | R. Giugliano | E. Braunwald | J. Halperin | S. Murphy | M. Mercuri | A. Waldo | J. Hanyok | S. Wiviott | M. Ruda | Y. Koretsune | W. Rużyłło | J. Weitz | C. Ruff | J. Špinar | L. Grip | Joshua Betcher | M. Shi | Indravadan Patel | Shirali P Patel
[1] G. Raskob,et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.
[2] G. Raskob,et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, New England Journal of Medicine.
[3] F. Lee,et al. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects , 2013, Clinical pharmacology in drug development.
[4] R. de Caterina,et al. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? , 2013, Vascular pharmacology.
[5] F. Lee,et al. Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor , 2013, American Journal of Cardiovascular Drugs.
[6] R. Giugliano,et al. Novel Oral Anticoagulants in Atrial Fibrillation: A Meta‐analysis of Large, Randomized, Controlled Trials vs Warfarin , 2013, Clinical cardiology.
[7] R. Little,et al. The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.
[8] W. Nelson,et al. Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients , 2012, Advances in Therapy.
[9] M. Samama,et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. , 2012, Thrombosis research.
[10] E. Antman,et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation , 2012, Thrombosis and Haemostasis.
[11] T. Shibano,et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents , 2011, Thrombosis and Haemostasis.
[12] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[13] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[14] P. Stiefelhagen. [Up to date in atrial fibrillation?]. , 2011, MMW Fortschritte der Medizin.
[15] R. Giugliano,et al. New oral antithrombotic strategies , 2011 .
[16] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[17] S. Connolly,et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation , 2010, Thrombosis and Haemostasis.
[18] H. Masumoto,et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers , 2010, Journal of clinical pharmacology.
[19] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[20] Draft Guidance. Guidance for Industry Non-Inferiority Clinical Trials , 2010 .
[21] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[22] A. Papaioannou,et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review , 2008, BMC geriatrics.
[23] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[24] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[25] John L.P. Thompson,et al. Missing data , 2004 .
[26] M. Rich,et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.
[27] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.